Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonists Drugs Market to Reach US$ 3.39 Billion by 2031, Driven by Endometriosis, Prostate Cancer, and Uterine Fibroids

According to DataM Intelligence, the global Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonists Drugs market reached US$ 1.64 billion in 2023 and is expected to reach US$ 3.39 billion by 2031, growing at a CAGR of 9.6% during the forecast period 2024-2031, driven by increasing incidence of hormone-dependent conditions such as endometriosis, prostate cancer, uterine fibroids, and precocious puberty, strong adoption of GnRH agonists like leuprolide and antagonists like elagolix/relugolix, expanding use in gynecology and oncology.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/gnrh-agonists-and-antagonists-drugs-market?jd

Key Mergers and Acquisitions
✦ January 2026: AbbVie Inc. acquired rights to a next-generation oral GnRH antagonist from a biotech partner to expand its portfolio beyond elagolix (Orilissa) for endometriosis and uterine fibroids.
✦ December 2025: Takeda Pharmaceutical Company Limited completed a strategic licensing deal for a novel GnRH antagonist candidate to strengthen its oncology and gynecology pipeline.
✦ November 2025: Ferring Pharmaceuticals acquired a specialty fertility biotech to enhance its GnRH agonist offerings for reproductive health and assisted reproduction applications.

Key Industry Developments
☑️ January 2026: Bayer AG, AbbVie Inc., and Ferring expanded patient access programs for GnRH agonists (e.g., leuprolide) and antagonists in endometriosis and prostate cancer, with new real-world evidence supporting long-term efficacy in specialty clinics.
☑️ December 2025: AstraZeneca and Merck KGaA advanced combination studies of GnRH therapies with PARP inhibitors for advanced prostate cancer, presenting interim data at major oncology congresses.
☑️ November 2025: Ipsen Pharma and TerSera Therapeutics LLC increased supply of GnRH agonists for precocious puberty and oncology, targeting hospitals and pediatric endocrinology centers.

Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=gnrh-agonists-and-antagonists-drugs-market

Market Segmentation Analysis
By Drug Type: GnRH Agonists hold the largest share due to established use of leuprolide, goserelin, and triptorelin in prostate cancer, endometriosis, and uterine fibroids; GnRH Antagonists grow fastest with rapid adoption of oral agents like elagolix and relugolix offering quicker onset and fewer flare-ups.

By Application: Gynecology dominates with major demand for endometriosis, uterine fibroids, and assisted reproduction; Oncology follows closely for prostate cancer hormone suppression; Others include precocious puberty, breast cancer, and central precocious puberty management.

By End-User: Hospitals lead due to need for injectable GnRH therapies, monitoring, and acute management; Specialty Clinics grow rapidly for long-term outpatient administration of oral antagonists and agonists; Others include fertility centers and urology practices.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/gnrh-agonists-and-antagonists-drugs-market?jd

Competitive Landscape / Key Players
✦ AbbVie Inc. - In January 2026, licensed a next-generation oral GnRH antagonist to expand beyond elagolix (Orilissa), and presented long-term data in late 2025 supporting sustained efficacy in endometriosis and fibroids.
✦ Takeda Pharmaceutical Company Limited - Licensed a novel GnRH antagonist candidate in December 2025, enhancing its oncology and reproductive health pipeline with planned Phase 2 trials in 2026.
✦ Ferring Pharmaceuticals - Acquired a fertility biotech in November 2025 to bolster GnRH agonist offerings for IVF and reproductive disorders, while expanding access programs for endometriosis patients.
✦ AstraZeneca - Advanced GnRH agonist combinations with PARP inhibitors for prostate cancer in December 2025, with interim Phase 3 data showing improved outcomes in advanced disease.
✦ Merck KGaA - Strengthened GnRH therapy partnerships in late 2025, focusing on oncology applications and supportive care for hormone-dependent cancers in specialty clinics.

Regional Insights
North America dominates the GnRH Agonists and Antagonists Drugs market with the largest revenue share in 2024, supported by high diagnosis rates of endometriosis, prostate cancer, and uterine fibroids, rapid FDA approvals (e.g., oral antagonists), advanced specialty care infrastructure, strong reimbursement for biologics and injectables, and significant R&D investment in hormone therapies.

Asia-Pacific is the fastest-growing region at 8.1% CAGR, fueled by rising awareness of reproductive and oncologic disorders, increasing healthcare access, growing specialty clinics and hospitals, government initiatives for women's health and cancer care, and expanding clinical trial participation by global players targeting inflammatory and fibrotic pathways.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.